Latest! Beijing new anti epileptic drugs first pass the consistency evaluation, Fosun hot selling antidepressants pass the consistency evaluation!

On May 21, Beijing New Pharmaceutical Co., Ltd announced that it had received the approval document of drug supplement application of "zuelacetam tablets" After examination, the 0.25g specification of this product passed the quality and efficacy consistency evaluation of generic drugs On the same day, Fosun Pharmaceutical also issued an announcement that its holding subsidiary Hunan Dongting Pharmaceutical Co., Ltd (hereinafter referred to as "Dongting pharmaceutical") had received the approval document for supplementary application for drugs (approval document No.: 2018b02873; original approval document No.: GJZ h20143391) of escitalopram oxalate tablets (specification: 10mg (calculated based on escitalopram)), which passed the consistency of generic drugs Evaluation According to the relevant national policies, the drug varieties through the consistency evaluation should be properly supported in the payment of medical insurance, and medical institutions should give priority to purchasing and selecting in clinical practice Zuoxiracetam is the only antiepileptic drug that can prevent the onset of epilepsy It is reported that the terminal market of antiepileptic drugs in China has reached 4 billion yuan in the past Levetiracetam tablets have a large variety potential and have a broad market prospect in China This time, Jingxin is the first one to pass the consistency evaluation, which is of great significance and will have an absolute market advantage Fosin's escitalopram oxalate tablet is an antidepressant and a single right-handed optical isomer of racemic citalopram, a derivative of dicyclohydrophthalein In 2017, the sales volume of Dongting pharmaceutical in China (excluding Hong Kong, Macao and Taiwan) was about 7.58 million yuan As of April 2018, Fosun Pharmaceutical has invested about 8.8 million yuan in R & D for the consistency evaluation of the drug at this stage (the above two data are not audited) at present, the listed escitalopram oxalate tablets in China include laishipu of Xi'an YANGSEN Pharmaceutical Co., Ltd., baishike of Shandong Jingwei Pharmaceutical Co., Ltd., etc According to the latest data of iqviachpa, in 2017, the sales volume of escitalopram oxalate tablets in China was about 1.09 billion yuan In addition, according to the mailing records, in addition to several confirmed products of the company, it is expected that the following products of the company also passed the consistency evaluation this time Information source: announcement of Jingxin and Fosun company, State Drug Administration, pharmaceutical intelligence data